Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for CRL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -0.08%
March 31, 2026 -1.49%
December 31, 2025 -27.79%
September 30, 2025 5.53%
June 30, 2025 5.11%
March 31, 2025 2.63%
December 31, 2024 -21.32%
September 30, 2024 6.96%
June 30, 2024 9.19%
March 31, 2024 7.36%
December 31, 2023 18.64%
September 30, 2023 8.57%
June 30, 2023 9.38%
March 31, 2023 10.10%
December 31, 2022 17.19%
September 30, 2022 9.87%
June 30, 2022 11.37%
March 31, 2022 10.42%
December 31, 2021 15.45%
September 30, 2021 11.74%
June 30, 2021 9.83%
March 31, 2021 7.75%
December 31, 2020 18.23%
September 30, 2020 13.80%
June 30, 2020 9.91%
Date Value
March 31, 2020 7.19%
December 31, 2019 11.65%
September 30, 2019 11.01%
June 30, 2019 6.74%
March 31, 2019 9.21%
December 31, 2018 10.01%
September 30, 2018 10.41%
June 30, 2018 9.03%
March 31, 2018 10.78%
December 31, 2017 -6.07%
September 30, 2017 11.42%
June 30, 2017 11.65%
March 31, 2017 10.54%
December 31, 2016 9.70%
September 30, 2016 8.85%
June 30, 2016 8.19%
March 31, 2016 10.59%
December 31, 2015 9.40%
September 30, 2015 10.85%
June 30, 2015 14.50%
March 31, 2015 9.87%
December 31, 2014 8.66%
September 30, 2014 9.86%
June 30, 2014 10.69%
March 31, 2014 10.90%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
IQVIA Holdings, Inc. 5.90%
Medpace Holdings, Inc. 17.16%
Fortrea Holdings, Inc. -1.95%
Avantor, Inc. 2.25%
Champions Oncology, Inc. -4.82%